AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time.
| Event details follow: | |
| Date: | Thursday, August 8th |
| Time: | 8:30 a.m. Eastern Time |
| Audio Webcast: | https://www.CassavaSciences.com/company-presentations |
| Or | |
| Audio Webcast: | https://edge.media-server.com/mmc/p/zjvmjjcr |
A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences’ website for 90 days following the webcast.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450 or This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.28 |
| Daily Change: | -0.10 -4.20 |
| Daily Volume: | 384,080 |
| Market Cap: | US$110.150M |
August 04, 2025 June 30, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
